Naturally occurring cobalamins have antimalarial activity

Chemaly, Susan M.; Chen, Chien-Teng; Zyl, Robyn L. van

doi:10.1016/j.jinorgbio.2007.01.006

Cited by 18 publications

(21 citation statements)

References 70 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same way, Chemaly et al [133] observed that cobalamins (cbls) also called vitamin B12 (corrin ring with a chemical structure close to the heme but the central iron atom is replaced by an atom of cobalt) possess antimalarial activity. Methylcobalamin (CH 3 -cbl), adenosylcobalamin (Ado-cbl), and aquacobalamin (H 2 O-cbl) (Figure 11) showed increased efficacy over the chloroquine; cyanocobalamin (CN-cbl) was a little more efficient than chloroquine.…”

Section: Current Topics In Malaria 218mentioning

confidence: 88%

Inactivation of Malaria Parasites in Blood: PDT vs Inhibition of Hemozoin Formation

Vanderesse¹,

Colombeau²,

Frochot³

et al. 2016

Current Topics in Malaria

View full text Add to dashboard Cite

Malaria causes hundreds of thousands of human deaths every year, and the World Health Assembly has made it a priority. To help eliminate this disease, there is a pressing need for the development and implementation of new strategies to improve the prevention and treatment, due in part to antimalarial drug resistances. This chapter focuses on two strategies to inactivate the malaria parasite in blood, which are photodynamic therapy (PDT) and inhibition of hemozoin formation. The PDT strategy permits either a control of the proliferation of mosquito larvae to develop some photolarvicides for the prevention or a photoinactivation of the malaria parasite in red blood cells (RBCs) to minimize infection transmission by transfusion. The inhibition of hemozoin formation strategy is used for the development of new antimalarial drug by understanding its formation mechanism.

show abstract

Section: Current Topics In Malaria 218mentioning

confidence: 88%

Inactivation of Malaria Parasites in Blood: PDT vs Inhibition of Hemozoin Formation

Vanderesse¹,

Colombeau²,

Frochot³

et al. 2016

Current Topics in Malaria

View full text Add to dashboard Cite

show abstract

“…The entire dose was repeated if vomiting occurred within 30 min after intake of the anti-malarial and half the dose if vomiting occurred between the first 30 min and 1 h after intake. Drugs such as vitamin C [23], vitamin B12 [24], retinol supplementation [25,26], that may influence anti-malarial drug activity were avoided during prescription of concomitant drugs. Similarly, antibiotics such as cotrimoxazole, macrolides, tetracycline and doxycycline were avoided during the period of follow up.…”

Section: Treatmentmentioning

confidence: 99%

Efficacy and safety of artesunate–amodiaquine and artemether–lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial

Béavogui

Camara

Délamou

et al. 2020

Malar J

View full text Add to dashboard Cite

Background: Anti-malarial resistance is a threat to recent gains in malaria control. This study aimed to assess the efficacy and safety of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the management of uncomplicated malaria and to measure the prevalence of molecular markers of resistance of Plasmodium falciparum in sentinel sites in Maferinyah and Labé Health Districts in Guinea in 2016. Methods: This was a two-arm randomised controlled trial of the efficacy of AL and ASAQ among children aged 6-59 months with uncomplicated Plasmodium falciparum malaria in two sites. Children were followed for 28 days to assess clinical and parasitological response. The primary outcome was the Kaplan-Meier estimate of Day 28 (D28) efficacy after correction by microsatellite-genotyping. Pre-treatment (D0) and day of failure samples were assayed for molecular markers of resistance in the pfk13 and pfmdr1 genes. Results: A total of 421 participants were included with 211 participants in the Maferinyah site and 210 in Labé. No early treatment failure was observed in any study arms. However, 22 (5.3%) participants developed a late treatment failure (8 in the ASAQ arm and 14 in the AL arm), which were further classified as 2 recrudescences and 20 reinfections. The Kaplan-Meier estimate of the corrected efficacy at D28 was 100% for both AL and ASAQ in Maferinyah site and 99% (95% Confidence Interval: 97.2-100%) for ASAQ and 99% (97.1-100%) for AL in Labé. The majority of successfully analysed D0 (98%, 380/389) and all day of failure (100%, 22/22) samples were wild type for pfk13. All 9 observed pfk13 mutations were polymorphisms not associated with artemisinin resistance. The NFD haplotype was the predominant haplotype in both D0 (197/362, 54%) and day of failure samples (11/18, 61%) successfully analysed for pfmdr1. Conclusion: This study observed high efficacy and safety of both ASAQ and AL in Guinea, providing evidence for their continued use to treat uncomplicated malaria. Continued monitoring of ACT efficacy and safety and molecular

show abstract

“…he entire dose was repeated if vomiting occurred within 30 minutes after intake of the antimalarial and half the dose if vomiting occurred between the first 30 minutes and 1 hour after intake. Drugs such as vitamin C [22], vitamin B12 [23], retinol supplementation [24,25], that may influence antimalarial drug activity were avoided. Similarly, antibiotics such as cotrimoxazole, macrolides, tetracycline and doxycycline were avoided during the period of follow up.…”

Section: Treatmentmentioning

confidence: 99%

Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea, 2016

Béavogui¹,

Camara²,

Délamou³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Antimalarial resistance is a threat to recent gains in malaria control. This study aimed to assess the efficacy and safety of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the management of uncomplicated malaria and to measure the prevalence of molecular markers of resistance of Plasmodium falciparum in sentinel sites in Maferinyah and Labé Health Districts in Guinea in 2016.Methods: This was a two-arm randomized controlled trial of the efficacy of AL and ASAQ in children aged 6-59 months with P. falciparum monoinfection in two sites. Children were followed for 28 days to assess clinical and parasitological response. The primary outcome was the Kaplan-Meier estimate of Day 28 (D28) efficacy after correction by microsatellite-genotyping. Pre-treatment (D0) and day of failure samples were assayed for molecular markers of resistance in the pfk13 and pfmdr1 genes.Results: A total of 421 participants were included with 211 participants in the Maferinyah site and 210 in Labé. No early treatment failure was observed in any study arms. However, 22 (5.3%) participants developed a late treatment failure, which were further classified as 2 recrudescences and 20 reinfections. The Kaplan-Meier estimate of the corrected efficacy at D28 was 100% for both AL and ASAQ in Maferinyah site and 99% (95% Confidence Interval: 97.2-100%) for ASAQ and 99% (97.1-100%) for AL in Labé. The majority of successfully analyzed D0 (98%, 380/389) and all day of failure (100%, 22/22) samples were wild type for pfk13. All 9 observed pfk13 mutations were polymorphisms not associated with artemisinin resistance. The NFD haplotype was the predominant haplotype in both D0 (197/362, 54%) and day of failure samples (11/18, 61%) successfully analyzed for pfmdr1.Conclusions: This study observed high efficacy and safety of both ASAQ and AL in Guinea, providing evidence for their continued use to treat uncomplicated malaria. Continued monitoring of ACT efficacy and safety and molecular makers of resistance in Guinea is important to detect emergence of parasite resistance and to inform evidence-based malaria treatment policies.

show abstract

Naturally occurring cobalamins have antimalarial activity

Cited by 18 publications

References 70 publications

Inactivation of Malaria Parasites in Blood: PDT vs Inhibition of Hemozoin Formation

Inactivation of Malaria Parasites in Blood: PDT vs Inhibition of Hemozoin Formation

Efficacy and safety of artesunate–amodiaquine and artemether–lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial

Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea, 2016

Contact Info

Product

Resources

About